Evidence map›Paper›PMID 35198439›Full record

ArticleFrontiers in oncology2022

The Styryl Benzoic Acid Derivative DC10 Potentiates Radiotherapy by Targeting the xCT-Glutathione Axis.

Shahin Sarowar, Davide Cirillo, Pablo Játiva, Mette Hartmark Nilsen, Sarah-Muheha Anni Otragane, Jan Heggdal, Frode Selheim, Valentín Ceña, Hans-René Bjørsvik, Per Øyvind Enger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Targeting glutathione metabolism for tumor radiosensitization (Review).International journal of molecular medicine · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Shahin SarowarOncomatrix Research Laboratory, Department of Biomedicine, University of Bergen, Bergen, Norway.
Davide CirilloDepartment of Chemistry, University of Bergen, Bergen, Norway.
Pablo JátivaUnidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Albacete, Spain.
Mette Hartmark NilsenOncomatrix Research Laboratory, Department of Biomedicine, University of Bergen, Bergen, Norway.
Sarah-Muheha Anni OtraganeOncomatrix Research Laboratory, Department of Biomedicine, University of Bergen, Bergen, Norway.
Jan HeggdalDepartment of Medical Physics, Haukeland University Hospital, Bergen, Norway.
Frode SelheimThe Proteomics Facility of the University of Bergen (PROBE), University of Bergen, Bergen, Norway.
Valentín CeñaUnidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Albacete, Spain.
Hans-René BjørsvikDepartment of Chemistry, University of Bergen, Bergen, Norway.
Per Øyvind EngerOncomatrix Research Laboratory, Department of Biomedicine, University of Bergen, Bergen, Norway.
University of Bergen · NOUniversity of Castilla-La Mancha · ESHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic tumors with moderate radiosensitivity account for most cancer-related deaths, highlighting the limitations of current radiotherapy regimens. The xCT-inhibitor sulfasalazine (SAS) sensitizes cancer cells to radiotherapy by blocking cystine uptake

Indexed as

gliomamelanomamiceoxidative stressradiosensitiserSARXCT

Identifiers

PMID35198439
PMCPMC8858948
OpenAlexW4210784902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.